


- Histamine is a β -imidazolylethylamine derivative present in all mammalian tissues.
- It was first discovered by **SIR HENRY DALE**.
- Its synthesis occurs in mast cells, parietal cells of gastric mucosa, CNS, periphery.
- It functions as an autocoid & one of the mediator involved in the allergic inflammatory responses.
- It has an important role in the regulation of gastric acid secretion.




BIOSYNTHESIS OF HISTAMINE

- Histamine is synthesized in cytoplasmic granules of its storage cells, mast cells & basophils.
- It is formed from naturally occurring amino acid, S-histidine, via the catalysis of the pyridoxal phosphate – dependent enzyme histidine decarboxylase/ aromatic decarboxylase.

INHIBITORS OF HISTIDINE DECARBOXYLASE

 $\Box \alpha$ -fluoromethyl histidine

Certain flavonoids



METABOLISM OF HISTAMINE

- Metabolism of histamine takes by the enzymatic inactivation.
- Enzymes that involve in the metabolism are:
 - 1. Histamine N-methyl transferase(HMT)
 - 2. Diamine oxidase.
- Histamine is metabolized as N- methylimidazole acetic acid , imidazole acetic acid riboside. Both are excreted through urine.

IMPORTANCE OF HISTAMINE

- It is not used therapeutically but in the past it has been used to test acid secreting capacity of stomach.
- To test bronchial hyperactivity in asthmatics.
- For diagnosis of pheochromocytoma, but these pharmacological tests are risky.
 - In pulmonary laboratories, histamine aerosol has been used as a provocative test of bronchial hyperactivity.
- To distinguish between real & pseudoanesthesia.

RECEPTORS

- Histamine receptors are belonging to the family of G-Protein coupled receptors.
- The sub types of histamine receptors are:

 \Box H₁

 \square H₂

 \square H₃

	\Box H ₄			
RECEPTOR	H_1	H_2	H_3	H_4
LOCATION 9	Brain,GIT,CVS Lymphocytes.	Myocardial cells,pariet al cells	CNS,myent ric plexus, gastric mucosa	Spleen,thymus ,T-cells, eosinophils. 7/10/2014

HISTAMINE ANTAGONISTS


- Drugs that block the action of histamine at H_1, H_2, H_3, H_4 receptors
- The development of antihistamines began by the discovery of PIPEROXAM.

1. Drugs that inhibits the histamine release.

- 2. Drugs that inhibits the action of released histamine
 - a. H₁ antagonists(first, second&third generations)
 - b. H₂ antagonists
 - c. H_3 antagonists


3. Drugs having dual action

GENERAL STRUCTURE OF ANTIHISTAMINES



- Ar is aryl: Phenyl, substituted phenyl, hetero aryl groups like
 2- pyridyl.
- \rightarrow Ar₁: Second aryl (or) aryl methyl group.
- \succ X: Connecting atom of O, C, (or) N.
- \succ (CH₂)n: Carbon chain usually ethyl.
- \triangleright NRR₁: Basic, terminal amine functional group. 7/10/2014

DRUGS THAT BLOCK THE HISTAMINE RELEASE




- These drugs act by stabilizing the mast cells & inhibit the release of histamine & other mediators of inflammation.
- Natural product KHELLIN led to the development of bis compounds.
- CROMOLYN nasal solution used for the prevention & treatment of allergic rhinitis.
- Oral concentrate used to treat the histaminic symptoms of mastocytosis.


DRUGS THAT BLOCK THE RELEASED HISTAMINE

- a) H₁ANTAGONISTS(FIRST GENERATION DRUGS):
- These are classical antihistamines.
- These are clinically used in the treatment of histamine mediated allergic conditions like allergic rhinitis, allergic conjuctivitis etc.,

CLASSIFICATION:

- a) Amino alkyl ethers.
- b) Ethylenediamine derivatives.
- c) Propyl amine derivatives.
- d) Phenothiazine derivatives.
- e) Piperazine derivatives.






STRUCTURE ACTIVITY RELATIONSHIP


- These are characterized by presence of OXYGEN connecting moiety.
 - Most compounds in this series are simple N,N-dimethyl ethanolamine derivatives.
- **CLEMASTINE** differs from basic structural pattern.
- Most amino alkyl ethers are optically active.
- The drugs in this group possess significant anticholinergic activity,
 - which may enhance the H_1 blocking action on exocrine secretion.
- This amino alkyl ethers have to penetrate the BBB and occupy central
 - H_1 receptor resulting the **DROWSINESS**.


b) ETHYLENEDIAMINE DERIVATIVES: **GENERAL STRUCTURE:** R Ar $CH_2 - CH_2 - N$ Ν \mathbf{R}_1 Ar1 **CHEMICAL** DRUG Ar Ar1 NAME 2-[Benzyl[2-(dime **TRIPELENN** Thylamino)ethyl]-CH₂-**AMINE** Amino]pyridine 2-[2-(Dimethyl **METHAPY** Amino)ethyl]2-**RILENE** Thienylamino CH_2 18 Pyridine.



SAR:

- [®] These are characterized by **NITROGEN** connecting atom.
- Phenbenzamine was first clinically useful member.
- Replacement of phenyl moiety of Phenbenzamine with a 2-pyridyl system yielded "tripelennamine"
- Replacement of benzyl group of tripelennamine with a 2-thienylmethyl group provided methapyriline.
- Replacement of tripelennamine with -2-pyridyl group with a pyrimidinyl moiety yields thonzylamine.
- ¹⁹ The anticholinergic & antiemetic action of these compounds are low.






SAR:


Phenyl substituent at P-position replaces with "Cl" is chlorpheniramine & "Br" is bromopheniramine.

- These halogenated pheniramines are more potent & have a longer duration of action.
- The agents in this class produce less sedation than the other classical antihistamines.



d) PHENOTHIAZINE DERIVATIVES:

GENERAL STRUCTURE:



DRUG	R	CHEMICAL NAME
PROMETHAZ INE	$CH_2N(CH_3)_2$ CH_3	(±)10-[2- (Dimethylamino)pro pyl]phenothiazine
TRIMEPRAZI NE	CH ₂ CH ₂ N(CH ₃) ₂ CH3	(±)10-[3- (Dimethylamino)-2- methylpropyl]phenothi azine.

SAR


Phenothiazine derivatives that contain a 2/3 carbon branched alkyl chain between alkyl chain between the ring system and terminal nitrogen atom. This differs the phenothiazine's from antipsychotic series in which an unbranched propyl chain is required.

PROMETHAZINE, the parent member of this series is moderately potent & with prolonged action & pronounced sedative side effects.
The combination of lengthening of side chain & substitution of lipophilic groups in 2nd position of aromatic ring results in compounds with decreased antihistaminic activity & increased psychotherapeutic properties.

METABOLISM:

These compounds undergo mono-di & N-dealkylation, sulfur oxidation, aromatic oxidation at 3rd position to yield phenol & N-oxidation.

DIBENZOCYCLOHEPTANES & DIBENZOCYCLOHEPTENES




These are the phenothiazine analogues in which sulfur atom is replaced by an isosteric vinyl group (cyproheptadine) or saturated ethyl bridge ²⁵(AZATIDINE).


7/10/2014

e) PIPERAZINE DERIVATIVES:

GENERAL STRUCTURE:



DRUG	R	R ₁	CHEMICAL NAME
CYCLIZINE	Η	CH ₃	1- (Diphenylmethyl)-4-methyl piperazine. 7/10/2014



SAR:

- ► These are ETHYLENE DIAMINE derivatives.
- ▶ Connecting moiety(X) is CHN group.

▶ These are moderatly potent, with low incidence of drowsiness. slow onset

of action & exhibit peripheral & central antimuscarnic activity.

²⁷ Primary structural difference is nature of para aromatic ring substitutent.

MECHANISM OF ACTION

• H₁ antagonists act by competitively inhibiting the effects of histamine

at H₁ receptor.

• H₁ receptor blockade results in decreased vascular permeability,

reduction of pruritus, relaxation of smooth muscle in the respiratory,


H₁ ANTAGONISTS (FIRST GENERATION)

- These are classical antihistamines.
- These are clinically used in the treatment of histamine mediated allergic conditions.
- These are mainly used in allergic rhinitis, allergic conjunctivitis, allergic dermatological conditions.


ADVERSE EFFECTS:

- \oplus The main adverse effect of H₁ antagonists first generation is SEDATION.
- This is evidenced by drowsiness, diminished alertness.
- This is due to their relative lack of selectivity for the PERIPHERAL H1
 RECEPTOR,.

SECOND GENERATION H₁ ANTAGONISTS(NON-SEDATIVE)




FEXOFENADINE




- These have a relative low affinity for central H₁ receptors & largely free from sedation.
- The 2nd generation drugs have little affinity for muscarnic,adrenergic receptors.
- TERFENADINE is a long acting H_1 antagonist.
- FEXOFENADINE is a primary oxidative metabolite of TERFENADINE&
 - does not cross the BBB.

THIRD GENERATION H₁ ANTIHISTAMINES CH_3 ClΗ СООН Η COOC₂H₅ LORATIDINE ACRIVASTINE


These are active metabolite derivatives of second generation drugs intended to have increased efficacy with fewer adverse drug reactions.










- * These are the result of modification of histamine structure.
- * The imidazole ring of histamine is not required for competitive antagonism of histamine at H_2
- Separation of ring & nitrogen group with the equivalent of 4 carbon chain is necessary for optimum antagonist activity.
- * The terminal nitrogen group should be polar, non-basic substituents for maximal activity.








This THIOPERAMIDE was first potent H3 antagonist used to treat sleep disorders.



This DOXEPINE, CHLORPROMAZINE are bind to the H4 receptor with high affinity.

DRUGS HAVING DUAL ACTION



- Both the drugs having the action of antihistaminic & mast cell stabilization.
- Both are used in allergic conjunctivitis.

USES OF ANTIHISTAMINES

ALLERGIC DISORDERS:

They effectively control certain immediate type of allergies like itching, urticaria, seasonal hay fever, allergic conjunctivitis & angioedema of lips eyelids etc.,

CETIRIZINE have adjuvant role in seasonal asthma.
PRURITIS:

> Antihistamines are first choice of drugs for idiopathic pruritus.
COMMON COLD:

> They donot effect the illness but may afford sympatomatic relief by anticholinergic & sedative actions.

As hypnotics eg: diphenhydramine & promethazine.

As "anti-tussives" Eg: diphenhydramine.
As "anti-emetic" Eg: meclizine
In "parkinsonism" Eg: promethazine , diphenhydramine.
In drug induced "acute dystonias" Eg: diphenhydramine, promethazine.

> To treat "motion & morning sickness" Eg: cyclizine, promethazine.

> To treat "vertigo" conditions Eg: cinnarizine.

